Jun 12, 2019
The study published in The New England Journal of Medicine set out to study the effect of the drug teplizumab in people at high risk for type 1 diabetes. According to recent Phase II clinical trials, in experimental immunotherapy conducted, the drug has been able to delay the onset of disease for the first tim...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper